Abstract
A neurologic deficit of sudden onset conforming to a vascular territory is a clear clinical indication that a patient is suffering from an acute stroke. However, the imagistic diagnostic confirmation is not always readily available. We are now able to offer comprehensive medical support for the patient after an acute stroke and to make a prodigious rehabilitation program after the damage is done, but this is not offering the chance for improvement. An opportunity to better diagnose ischemic stroke seems to be available by using neuronal biomarkers. Extensive research is being conducted in this field and useful information is beginning to gather. This mini-review aims to highlight selected studies that appear to be of particular interest for the clinical neurologist. The most promising biomarkers (or rather panels of biomarkers) are presented with their clinical usefulness and limitations.

Keywords: neuronal biomarker, ischemic stroke, early diagnosis, biomarker panel
Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-dependent endopeptidases responsible for turnover and degradation of extracellular matrix proteins. Cerebral tissue expression of MMP-9 is normally minimal, but increases in MMP-9 were discovered in the ischemic brain [8,9]. They have a dual role during ischemic stroke: a deleterious one in the acute phase, when they are responsible for the disruption of the blood–brain barrier, neuronal cell death and hemorrhage after stroke, and a healing role during brain regeneration and neurovascular remodeling in the later tissue repair phase. Although the blood level of the MMPs rises in the wake of both ischemic and hemorrhagic stroke, the MMP-9 blood concentrations are best characterized in ischemic lesions. They have been identified as a predictor of infarct volume as measured with diffusion-weighted MRI [10] and the biomarker is further correlated with the effective application of thrombolytic therapy [11]. Blood MMP-9 concentrations in stroke patients treated with rtPA were significantly higher than those in untreated patients [12]. Hyper acute MMP-9 blood concentrations are considered a predictor of further hemorrhagic complications after rtPA administration.

Apolipoprotein CIII (Apo CIII) is present in normal plasma at 0.1 g/L and is mainly found in VLDL but also in HDL and LDL particles. It is associated with atherogenesis both by lipid mechanisms, direct effects on endothelial cells (by stimulating the adhesion of monocytes to the endothelial bed), and endothelial dysfunction [13]. Apo CIII is currently considered an important factor in the atherosclerotic phase of the cardiovascular disease; its role in late, more acute, thrombotic events or as a neuronal biomarker in stroke has been less explored so far [14].

S100B is a low molecular weight glial protein that belongs to a multigenic family of calcium-mediated proteins and has its name derived from the fact that the protein is 100% soluble in ammonium sulfate at neutral pH. Several studies have demonstrated that serum S100B concentrations are increased significantly following stroke [15,16].

It seems though that this marker should better be used for its prognostic value following stroke rather than for acute differential diagnostic. After transient ischemic attacks, the blood levels of S100B have minimal variations, while during stroke the serum levels rise, with a peak after 24 hours [17]. Furthermore, the blood levels of S100B correlate with the extent of the brain lesion and with outcome. The peak and the area under curve levels correlated in a recently published study with subacute infarct volume and the correlations were stronger when measured after 24 h than closer to admission [18].

The substance was also studied as a marker for brain damage during surgical interventions (as a biochemical marker of brain ischemic damage after the treatment of carotid stenosis). In a series of patients treated for atherosclerotic carotid stenosis there were 16 patients with increased postoperative levels of S100B: three affected by postoperative stroke, two patients with minor stroke, one patient with fatal stroke and 12 patients with uneventful neurological outcome and positive brain imaging. The blood levels of S100B returned to normal within the first 24 hours for the patients with positive brain imaging and without clinical manifestations, after 120 and 144 hours for the patients with minor stroke and it never returned to normal for the patient with the fatal stroke [19].

In the first few hours after the onset of stroke, high blood levels of S100B should be seen as a marker of brain-blood barrier dysfunction rather than as an indicator of infarct size, as the latter is not yet established at this early point in time. Therefore, S100B may be used as a predictor for the hemorrhagic transformation of an ischemic stroke [20]. Furthermore, studies have shown that S100B was significantly increased after stroke onset compared with controls and correlated with the infarct volume, stroke severity and functional outcome. High blood levels that fail to normalize after more than 120 hours are regarded as a possible marker for ongoing ischemia [21].

The Neuron-Specific Enolase (NSE), the isoenzyme y of the enolase is a phosphopyruvate hydratase, a metalloenzyme responsible for the catalysis of the conversion of 2-phosphoglycerate to phosphoenolpyruvate, the ninth and penultimate step of glycolysis. It has been studied for decades as a biomarker for cerebral tissue damage [22] and most studies showed that the peak levels of NSE in serum were found within the first 96 hours after cerebral infarction [23,24]. Peak level of NSE best reflects the final infarct volume and thus carries mainly a prognostic value, its use during the first hours after onset being unrewarding. Serial measurements of NSE levels seem to be useful markers for ongoing brain ischemia [25].

N-methyl-D-aspartic acid (NMDA) receptor binds the glutamate neurotransmitter; after neuronal death fragments of this receptor and later antibodies against them are released into the blood stream. Whereas the synthesis of the antibodies requires a certain amount of time and thus limiting the use during the acute phase, NR1 and NR2 subunits of the receptor are readily released into the blood stream after the onset of stroke. The fragmentation of the NR2 subunit into the peptides NR2A and NR2B is caused by ischemia or neurotoxicity, thus offering the chance to discriminate between ischemic and hemorrhagic events [26]. The NMDA receptor peptide is an indicator of glutamate excitotoxicity associated with acute stroke pathophysiology and can be used in the diagnosis of acute ischemic stroke within 3 hours from symptom onset.

The combination of clinical tests and blood biomarkers was also extensively studied. The markers t-PA and NT-proBNP were associated in a recent study positively and significantly (p < 0.01) with a diagnosis of transient cerebral ischemia or stroke and a model
containing the FAST (Face Arm Speech Test), age, systolic blood pressure, NT-proBNP and t-PA had a better sensitivity (88%, p < 0.006) and a better specificity (48%, p = 0.04) than the FAST test alone. The authors concluded that the panels of biomarkers may marginally improve diagnosis, but their practicability is uncertain, and requires further study [27].

The proteins released from cerebral ischemic tissue were studied in an experimental design in an excellent study recently published [28]. More than 2200 proteins were identified from the ischemic hemisphere with < 1.0% false discovery rate; the data were processed with data mining technologies and proteins having an involvement in the energy metabolism (Pygb, Atp5b), glutamate excitotoxicity (Slc1a3, Glu1d1), neuro-inflammation (Tf, C3, Alb), and cerebral plasticity (Gfap, Vim, Gap43) were cited as having a diagnostic value for ischemic stroke. Several regulated proteins (Cask1, Shank3, Kpn1b, Uchl1, Mtap6, Epb4.1l1, Apba1, and Ube1x) novel in the context of stroke were also discovered.

Clinical-diffusion mismatch (CDM; National Institutes of Health Stroke Scale score ≥ 8 and diffusion-weighted imaging lesion volume < 25 mL) has been suggested as a surrogate of ischemic brain at risk of infarction and might be used to recognize salvageable ischemic tissue. High levels of interleukin-10, tumor necrosis factor-α, and glutamate as well as low levels of neuron-specific enolase, interleukin-6, and active matrix metalloproteinase-9 are associated with CDM, thus offering diagnostic and prognostic information [29].

Blood measurements of biomarkers of brain damage and activation of the coagulation system may potentially serve as novel diagnostic tools for stroke subtypes. Ninety-seven stroke patients were prospectively investigated and the combination of glial fibrillary acidic protein (GFAP) and it was discovered that activated protein C-protein C inhibitor complex (APC-PCI) levels in patients with NIHSS score of more than 3 had a sensitivity and negative predictive value of 100% for ruling out intracerebral hemorrhage [30].

In a pilot study for the diagnosis of ischemic stroke within 6 hours from symptom onset that included brain natriuretic peptide, C-reactive protein, D-dimer, MMP-9, and protein S100B, a sensitivity of 81% and a specificity of 70% in diagnosing ischemic stroke, were recorded [31]. However, these encouraging results were not validated in prospective multicentre trials. After assessing the data from more than 1,100 patients presenting with symptoms suspicious for stroke with multivariate analysis, the authors concluded that the panel was capable of only moderately differentiating between stroke patients (IS, ICH) and mimics, with a sensitivity of 86% and a specificity of 37% for the discrimination of stroke patients from mimics. The diagnostic accuracy of this biomarker panel was clearly imperfect. Nevertheless, they claimed that a point-of-care algorithm might be feasible to aid in the early management of patients with symptoms suspicious for stroke [32].

Plasma samples from 223 stroke patients (including ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage) and from 214 healthy individuals were screened for more than 50 serum biomarkers. Astroglial protein S100B, B-type neurotrophic growth factor, von Willebrand factor (vWF), matrix metalloproteinase-9 (MMP-9), and monocyte chemotactic protein-1 were identified to be associated with stroke. The data on 65 patients with suspected ischemic stroke and 157 healthy controls revealed that protein S100B, MMP-9, vascular cell adhesion molecule and vWF were identified as being associated with ischemic stroke. The combined model revealed both a 90% sensitivity and specificity for predicting ischemic stroke [33,34].

The field of stroke biomarkers is about to take a huge leap due to advances in proteomics and genomics [35]. The new fields of research are the peripheral blood mononuclear immune cells, messenger RNA expression studies and oligonucleotide microarrays. Multiple gene expression studies of the activation of the immune system show promise in identifying markers of the ischemic cascade activated by acute stroke. Peripheral blood lymphocytes are key players in the evolution of brain tissue injury in ischemic stroke and are selectively activated to infiltrate the ischemic brain areas. These inflammatory immune cells exacerbate ischemic reperfusion and also mediate cell repair and tissue remodeling [36].

Messenger RNA expression studies have recently been introduced in the field of acute stroke. The potential for discovery of new candidate biomarkers is highly promising. In a mouse model, virsinin-like protein 1 was identified as a potential candidate for an acute blood-borne marker of ischemic stroke [37]. PARK7 protein and nucleoside diphosphate kinase A in the spinal fluid were identified as candidates for ischemic stroke biomarkers. Ischemic stroke could be diagnosed by PARK7 with a sensitivity of 58% and specificity of 90% and by nucleoside diphosphate kinase A with a sensitivity of 67% and a specificity of 90% [38].

Reproducible gene expression patterns within 24 hours after ischemic stroke have been identified [39]. The genes expressing amphiphysin and interleukin-1 receptor 2 are up-regulated after intracranial hemorrhage and can help identifying ischemic stroke subtypes. Lymphocyte gene expression along with circulating stem cells is involved in tissue repair and recovery after stroke [40].

Hemorrhagic transformation is a significant complication following ischemic stroke. The identification of patients at increased risk of hemorrhage could help reduce the incidence of this complication and potentially allow the extension of the time window for t-PA administration in selected patients [41]. Several biomarkers have also been associated with an increased risk of hemorrhage following administration of t-PA, including MMP-9, c-FN, PAI-1, TAFI and S100B.
Cellular fibronectin (c-Fn) is another factor that has been associated with increased hemorrhagic transformation. Cellular-Fn is synthesized by endothelial cells and is elevated following vascular injury including ischemic stroke. A study showed c-Fn levels > 3.6 ug/ml predict the development of hemorrhagic transformation following tPA use with a sensitivity of 100% and specificity of 96% [42].

Conclusions

Biomarkers can play many useful roles in neurology. Early diagnosis and immediate therapeutic interventions are important factors to reduce the extent of brain tissue damage in case of ischemic stroke and the risk of stroke-related death. The clinical relevance of all candidate markers needs to be carefully validated in future controlled clinical trials with analysis geared toward focused clinical questions. The field of neuronal biomarkers currently offers a chance of improving the results of the medical management of acute ischemic stroke.

Stroke biomarkers await prospective validation studies. Clinical utility and cost-effectiveness need to be established before biomarkers can be used routinely in clinical practice. The neurologists wait for evidence on whether the use of the neuronal biomarkers can improve patient care.

Acknowledgments

This work was supported by CNCSIS – UEFISCSU, project number PNII – IDEI 2621/ 2008.

References

1. Chalela JA, Kidwell CS, Nentwich LM et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007; 369:293-298.
2. Whiteley W, Tseng MC, Sanderson P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke. 2008; 39:2902-2909.
3. Marginean IC, Stanca DM, Vacaras V, Soritau O, Marginean M, Muresanu DF. Plasmatic markers in hemorrhagic stroke. J Med Life. 2011 May 15; 4(2):148-50.
4. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. 2009; 111:483-495.
5. Saenger KA, Christenson RH. Stroke Biomarkers: Progress and Challenges for Diagnosis, Prognosis, Differentiation, and Treatment. Clinical Chemistry. January 2010; 56, 1, 21-33.
6. Testai FD, Aiyagari V. Acute hemorrhagic stroke pathophysiology and medical interventions: blood pressure control, management of anticoagulant-associated brain hemorrhage and general management principles. Neurol Clin. 2008; 26:963-985.
7. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006; 5:53-63.
8. Clark AW, Krekoski CA, Bou S-S, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997; 238:53-56.
9. Anthony DC, Ferguson B, Matyazk MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol. 1997; 23:406-415.
10. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003; 107:598-603.
11. Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernández-Cadenas I et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke. 2005; 36:1415-1420.
12. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006; 66:1550-1555.
13. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinhas FW, Sacks FM. Apolipoprotein CII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006 Feb 7; 113(5):691-700.
14. Olivieri O, Martinelli N, Baroni M, Branchini A, Girelli D, Friso S, Pizzolo F, Bernardi F. Factor II activity is similarly increased in patients with elevated apolipoprotein CII and in carriers of the factor II 20210A allele. J Am Heart Assoc. 2015 Nov 15; 2(6):e000440. doi: 10.1161/JAHA.113.000440.
15. Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers if brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci. 2004; 227:49-53.
16. Buttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke. 1997; 28:1961-1965.
17. Elting JW, de Jager AE, Teelken AW, Schaaf MJ, Maurits NM, van der Naalt J et al. Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci. 2000; 181:104-110.
18. Ahmad O, Wardlaw J, Whiteley WN. Correlation of Levels of Neuronal and Gial Markers with Radiological Measures of Infarct Volume in Ischaemic Stroke: A Systematic Review. Cerebrovasc Dis. 2011 Dec 1; 33(1):47-54.
19. Scarcello E, Morrone F, Piro P, Tarstano S, Intiriet F, Vaccarella S, Guerra E, Serra R, de Francisca S. Protein-S-100B as biochemical marker of brain ischemic damage after treatment of carotid stenosis. Ann Vasc Surg. 2011 Oct; 25(7):975-8.
20. Foerch C, Wunderlich MT, Dvorak F et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38:2491-2495.
21. Nash DL, Bellolio MF, Stead LG. S100 as a marker of acute brain
ischemia: a systematic review. Neurocrit Care. 2006; 8(2):301-7.

22. Persson L, Härdemark HG, Gustafsson J, Rundström G, Mendel-Hartvig I, Esscher T, Palmén S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987; 18:911-918.

23. Cunningham RT, Young IS, Winder J, O’Kane MJ, McKinstry S, Johnston CF, Dolan OM, Hawkins SA, Buchanan KD. Serum neuore specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur J Clin Invest. 1991; 21:497-500.

24. Cunningham RT, Watt M, Winder J, McKinstry S, Lawson JT, Johnston CF, Hawkins SA, Buchanan KD. Serum neuone-specific enolase as an indicator of stroke volume. Eur J Clin Invest. 1996; 26:298-303.

25. Anand N, Stead LG. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis. 2005; 20(4):213-9.

26. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skorometz AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003 Oct; 49(10):1752-62.

27. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N et al. Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovasc Dis. 2011; 32(2):141-7.

28. Datta A, Jingru Q, Khor TH, Teo MT, Heese K, Sze SK. Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/ reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers. J Proteome Res. 2011 Nov 4; 10(11):5199-213.

29. Rodríguez-Yáñez M, Sobrino T, Arias S, Vázquez-Herrero F, Brea D, Blanco M et al. Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke. Stroke. 2011 Oct; 42(10):2813-8.

30. Undén J, Strandberg K, Malm J, Campbell E, Rosengren L, Stenflo J, Andsberg G. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol. 2009 Jan; 256(1):72-7.

31. Laskowitz DT, Blessing R, White WD, Lynch JR, Jauch EC. Panel of biomarkers predicts stroke. Ann N Y Acad Sci. 2005 Aug; 1053:30.

32. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke. 2009; 40:77-85.

33. Reynolds MA, Kirchick HJ, Dahlen JR et al. Early biomarkers of stroke. Clin Chem. 2003; 49:1733–1739.

34. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004; 35:57-63.

35. Bettermann K. Biomarkers for stroke: in search of fingerprints. J Stroke Cerebrovasc Dis. 2011 May-Jun; 20(3):173-6.

36. Baird AE. The forgotten lymphocyte: Immunity and stroke. Circulation. 2006; 113, 2035-6.

37. Laterza OF, Modur VR. Identification of novel brain biomarkers. Clin Chem. 2006; 52, 1713-21.

38. Allard L, Burkhard PR, Lescuyer P et al. Park7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem. 2005; 51, 2043-51.

39. Barr TL, Conley Y, Ding J. Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology. 2010; 75, 1009-14.

40. Baird AE. Genetics and genomics of stroke: novel approaches. J Am Coll Cardiol. 2010; 56, 245-53.

41. Jickling GC, Sharp FR. Blood biomarkers for ischemic stroke. Neurotherapeutics. 2011; 8:349-60.

42. Foorch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M, Alvarez-Sabin J, Wallwich CW, Molina CA, Steinmetz H, Sitzer M, Montaner J. Elevated serum s100b levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke. 2007; 38:2491-2495.